Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator, Mark A. Miller, M.D., at the Digestive Disease Week 2009 conference in Chicago.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

The additional data presented today for the first time focused on other patient risk factors believed to be predictive of CDI recurrence following treatment. These risk factors include serum albumin levels, white blood cell (WBC) count and temperature, and non-BI (NAP1/027) strains. The data showed that fidaxomicin overall demonstrated a lower recurrence rate compared to oral vancomycin (Vancocin(R)) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains. Vancocin is currently the only FDA approved therapy for CDI.

Recurrence Rates by Subgroup (per protocol)

    -------------------------------------------------------------------------
    Risk Factors                         Fidaxomicin     Vancocin(R) capsules
                                         (200mg bid)         (125mg qid)
    -------------------------------------------------------------------------
    White Blood Cell Count /Temp
    -------------------------------------------------------------------------
    WBC < 15,000 uL and Temp
     < 38 degrees C                     10.7% (17/159)      22.4% (35/156)
    WBC 15-25,000 uL or Temp 38
     degrees - 39 degrees C             12.0% (3/25)        20.0% (6/30)
    WBC > 25,000 uL or Temp
   
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a ... development and manufacture of highly valued cardiac markers used in early detection of ... with protein chemistry has led to the development and commercialization of important cardiac ...
(Date:8/26/2015)... 26, 2015 Israel Proves Its Place in ... st place  Wayerz comes in 5 th ... by venture capital fund JVP, with Chinese consulting firm ... China , Israel , ... Impressive achievement for the Israeli representatives in the final round ...
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... PRC ... to develop new business relationships with local sponsors in southern California. The Clinical Trial ... their drug development processes and regulatory pathways., , Stem ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets ... in Knapp, Wis. The company has added a AS16 Sharples centrifuge to harvest ... collection during bacterial or fungal fermentation process development. , The new centrifuge ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New centrifuge and fermentor expand product development capacity at Vets Plus 2
... WASHINGTON, June 11 Syngenta today ... to add an innovative antitoxin crop protection technology to the ... which is aimed at reducing aflatoxin, a toxin that can ... heat and drought stress. , , "The acquisition ...
... PharmaNet Development Group, Inc., a leading provider of clinical development services ... its participation at several international professional meetings during the month of June. ... 45th Drug Information Association (DIA) Annual Meeting, ... 321, ...
... Study to Evaluate FDA-Approved Topical Anesthetic Pretreatment , ... Inc. (Nasdaq: NGSX ) announced today that ... its proposed study to evaluate Qutenza(TM) in patients with ... anesthetic. As part of its ongoing new drug application ...
Cached Biology Technology:Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 2Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 3PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June 2NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 2NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 3NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 4
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... This release is available in German . ... in many animal species. During mating season male testosterone ... and masculine features. Male bonobos, however, invest much more ... levels would collide with this increased tendency towards forming ...
... PROVIDENCE, R.I. [Brown University] For the 26 million ... way to check glucose levels. It is invasive and ... working on a new sensor that can check blood ... The technique takes advantage of a convergence of ...
... Spanish . There are some jobs ("dirty ... a certain amount of social rejection towards the people who ... to moral conflicts and ethical decisions related to performing those ... perspective, as in the case of a police officer who ...
Cached Biology News:Bonobos' unusual success story 2Biochip measures glucose in saliva, not blood 2Biochip measures glucose in saliva, not blood 3Moral imagination as a key to overcoming work-related stigmas 2
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
... NOS activity by monitoring the conversion of ... simple, sensitive, and specific for NOS activity ... and purified enzyme preparations. The kit includes ... reactions. Radiolabeled arginine and NADPH are not ...
Biology Products: